查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594696

口服固體製劑契約製造市場：按產品、機制和最終用戶分類 - 全球預測 2025-2030

Oral Solid Dosage Contract Manufacturing Market by Product (Capsules, Granules, Gummies), Mechanism (Controlled-Release, Delayed-Release, Immediate-Release), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年口服固體製劑契約製造市值為408.3億美元，預計到2024年將達到441.6億美元，複合年成長率為8.63%，到2030年將達到729.1億美元。

口服固體製劑（OSD）契約製造是指將錠劑、膠囊等固態劑型的製造委託給專門的第三方機構。這種方法可以幫助製藥公司最佳化生產成本、利用先進技術並快速擴大營運規模。這項需求源自於縮短藥物上市時間、應對複雜配方挑戰以及遵守嚴格監管要求的壓力。 OSD契約製造在各種應用中發揮重要作用，包括學名藥製造、高效價藥物和新型藥物傳輸系統，最終用途涵蓋品牌製藥和生物技術公司。關鍵的成長要素包括對學名藥的需求不斷增加、連續生產等製造流程的技術進步以及慢性病盛行率的增加推動藥品消費。

主要市場統計
基準年[2023] 408.3億美元
預測年份 [2024] 441.6億美元
預測年份 [2030] 729.1億美元
複合年成長率（%） 8.63%

人工智慧和物聯網等數位技術的融合正在創造新的商機，提高效率和可追溯性。公司可以透過投資智慧製造方法來利用這一點。然而，監管障礙、品管問題和供應鏈中斷等限制帶來了重大挑戰。需要創新的領域是開發更永續的製造流程、解決環境問題並符合全球永續性趨勢。另一個有前景的途徑是個人化醫療，契約製造可以提供針對利基市場的解決方案。

隨著市場競爭的加劇以及多家公司不斷投資於研發以推出新穎的解決方案，策略夥伴關係關係至關重要。駕馭這一複雜的環境需要對技術整合、監管變化和客戶需求有敏銳的了解。企業也應專注於加強供應鏈彈性並擁抱數位轉型，以保持競爭優勢。透過利用這些策略，公司不僅可以確保合規性和效率，而且還可以處於 OSD契約製造市場創新的前沿。

市場動態：快速發展的口服固體製劑契約製造市場的關鍵市場洞察

口服固體製劑的契約製造市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 製藥公司擴大採用外包服務
    • 專利到期和學名藥生產增加
    • 需要具有成本效益的藥物開發過程
  • 市場限制因素
    • 缺乏經驗豐富的技術人員
  • 市場機會
    • 藥物開發技術的進步
    • CDMO 增加投資以擴大口服固態劑型 (OSD) 開發
  • 市場挑戰
    • 嚴格的監管核准標準

波特五力：開拓口服固體製劑契約製造市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解口服固體製劑契約製造市場的外部影響

外部宏觀環境因素在塑造口服固體製劑契約製造市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解口服固體製劑契約製造市場的競爭狀況

口服固體製劑契約製造市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV定位基質口服固體製劑契約製造市場供應商的績效評估

FPNV定位矩陣是評估口服固體製劑契約製造市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製口服固體製劑契約製造市場的成功之路

對於希望加強在全球市場的影響力的公司來說，口服固體製劑契約製造市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 藥廠加大外包服務引進力度
      • 專利到期和學名藥生產增加
      • 需要具有成本效益的藥物開發過程
    • 抑制因素
      • 缺乏經驗豐富的技術人員
    • 機會
      • 藥物開發技術不斷進步
      • CDMO 增加投資以擴大口服固體製劑(OSD) 開發
    • 任務
      • 嚴格的監管核准標準
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章口服固體製劑契約製造市場：依產品

  • 膠囊
  • 顆粒
  • 軟糖
  • 菱形
  • 菱形
  • 粉末
  • 藥片

第7章口服固體製劑契約製造市場：依組織分類

  • 控釋
  • 延遲釋放
  • 即時釋放

第8章口服固體製劑契約製造市場：依最終用戶分類

  • 主要企業
  • 中型企業/中小企業
  • Start-Ups和學名藥公司

第9章北美及南美口服固體製劑契約製造市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太口服固體製劑契約製造市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲口服固體製劑的契約製造市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Aenova Holding GmbH
  • Alcami Corporation, Inc.
  • Aphena Pharma Solutions
  • Ardena Holding NV
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Corden Pharma International GmbH
  • GlaxoSmithKline PLC
  • Hermes Pharma GmbH
  • Jubilant Pharma Holdings Inc.
  • Lonza Group Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Piramal Group
  • Recipharm AB
Product Code: MRR-0D217D5AE60A

The Oral Solid Dosage Contract Manufacturing Market was valued at USD 40.83 billion in 2023, expected to reach USD 44.16 billion in 2024, and is projected to grow at a CAGR of 8.63%, to USD 72.91 billion by 2030.

Oral Solid Dosage (OSD) Contract Manufacturing refers to the outsourcing of the production of solid pharmaceutical forms, such as tablets and capsules, to specialized third-party organizations. This approach supports pharmaceutical companies in optimizing production costs, accessing advanced technologies, and scaling operations rapidly. The necessity arises from the increasing pressure to reduce time-to-market for drugs, manage complex formulation challenges, and comply with stringent regulatory requirements. OSD contract manufacturing is critical in various applications, including generic drug production, high-potency drugs, and novel drug delivery systems, with end-use spanning both branded pharmaceuticals and biotechnology firms. Key growth factors include escalating demand for generics, technological advancements in manufacturing processes such as continuous production, and the increasing prevalence of chronic diseases which boost drug consumption.

KEY MARKET STATISTICS
Base Year [2023] USD 40.83 billion
Estimated Year [2024] USD 44.16 billion
Forecast Year [2030] USD 72.91 billion
CAGR (%) 8.63%

Emerging opportunities are being driven by the integration of digital technologies like AI and IoT, improving efficiency and traceability. Companies can capitalize on this by investing in smart manufacturing practices. However, limitations such as regulatory hurdles, quality control issues, and supply chain disruptions pose significant challenges. An area for innovation is the development of more sustainable manufacturing processes, addressing environmental concerns and aligning with global sustainability trends. Another promising avenue is personalized medicine, where contract manufacturers can provide tailored solutions for niche markets.

The market exhibits significant competitive intensity with several players continually investing in R&D to introduce novel solutions, making strategic partnerships vital. Successful navigation of this intricate landscape requires a keen understanding of technology integration, regulatory changes, and customer demands. Businesses should also focus on enhancing supply chain resilience and embracing digital transformation to maintain competitive advantage. By leveraging these strategies, companies not only ensure compliance and efficiency but also position themselves at the forefront of innovation in the OSD contract manufacturing market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oral Solid Dosage Contract Manufacturing Market

The Oral Solid Dosage Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing adoption of outsourcing services by pharmaceutical companies
    • Increasing patent expiration and generic drug manufacturing
    • Need for cost-effective drug development process
  • Market Restraints
    • Less availability of experienced technical staff
  • Market Opportunities
    • Increase in the advancement of drug development technology
    • Rising investments by CDMOs to expand the oral solid dosage (OSD) development
  • Market Challenges
    • Strict approval criteria by regulatory authorities

Porter's Five Forces: A Strategic Tool for Navigating the Oral Solid Dosage Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oral Solid Dosage Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oral Solid Dosage Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oral Solid Dosage Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oral Solid Dosage Contract Manufacturing Market

A detailed market share analysis in the Oral Solid Dosage Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oral Solid Dosage Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oral Solid Dosage Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oral Solid Dosage Contract Manufacturing Market

A strategic analysis of the Oral Solid Dosage Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oral Solid Dosage Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Aenova Holding GmbH, Alcami Corporation, Inc., Aphena Pharma Solutions, Ardena Holding NV, Boehringer Ingelheim International GmbH, Cambrex Corporation, Corden Pharma International GmbH, GlaxoSmithKline PLC, Hermes Pharma GmbH, Jubilant Pharma Holdings Inc., Lonza Group Ltd., Novartis AG, Pfizer Inc., Piramal Group, and Recipharm AB.

Market Segmentation & Coverage

This research report categorizes the Oral Solid Dosage Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Capsules, Granules, Gummies, Lozenges, Pastilles, Powders, and Tablets.
  • Based on Mechanism, market is studied across Controlled-Release, Delayed-Release, and Immediate-Release.
  • Based on End-User, market is studied across Large-Size Companies, Medium- & Small-Size Companies, and Startups & Generic Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of outsourcing services by pharmaceutical companies
      • 5.1.1.2. Increasing patent expiration and generic drug manufacturing
      • 5.1.1.3. Need for cost-effective drug development process
    • 5.1.2. Restraints
      • 5.1.2.1. Less availability of experienced technical staff
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in the advancement of drug development technology
      • 5.1.3.2. Rising investments by CDMOs to expand the oral solid dosage (OSD) development
    • 5.1.4. Challenges
      • 5.1.4.1. Strict approval criteria by regulatory authorities
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oral Solid Dosage Contract Manufacturing Market, by Product

  • 6.1. Introduction
  • 6.2. Capsules
  • 6.3. Granules
  • 6.4. Gummies
  • 6.5. Lozenges
  • 6.6. Pastilles
  • 6.7. Powders
  • 6.8. Tablets

7. Oral Solid Dosage Contract Manufacturing Market, by Mechanism

  • 7.1. Introduction
  • 7.2. Controlled-Release
  • 7.3. Delayed-Release
  • 7.4. Immediate-Release

8. Oral Solid Dosage Contract Manufacturing Market, by End-User

  • 8.1. Introduction
  • 8.2. Large-Size Companies
  • 8.3. Medium- & Small-Size Companies
  • 8.4. Startups & Generic Pharmaceutical Companies

9. Americas Oral Solid Dosage Contract Manufacturing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Oral Solid Dosage Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Oral Solid Dosage Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aenova Holding GmbH
  • 2. Alcami Corporation, Inc.
  • 3. Aphena Pharma Solutions
  • 4. Ardena Holding NV
  • 5. Boehringer Ingelheim International GmbH
  • 6. Cambrex Corporation
  • 7. Corden Pharma International GmbH
  • 8. GlaxoSmithKline PLC
  • 9. Hermes Pharma GmbH
  • 10. Jubilant Pharma Holdings Inc.
  • 11. Lonza Group Ltd.
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Piramal Group
  • 15. Recipharm AB

LIST OF FIGURES

  • FIGURE 1. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GRANULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GUMMIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY LOZENGES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PASTILLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CONTROLLED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY DELAYED-RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY LARGE-SIZE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MEDIUM- & SMALL-SIZE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STARTUPS & GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023